Thérapie

Effectiveness of Genotype-Specific Tricyclic Antidepressant Dosing in Patients With Major Depressive Disorder

Cornelis F. Vos, Sophie E. ter Hark, Arnt F. A. Schellekens, Jan Spijker, Annemarie van der Meij, Anne J. Grotenhuis, Raluca Mihaescu, Wietske Kievit, Rogier Donders, Rob E. Aarnoutse, Marieke J. H. Coenen and Joost G. E. Janzing
JAMA Network Open 6 (5) e2312443 (2023)
DOI: 10.1001/jamanetworkopen.2023.12443
Voir cet article

Chen Shen, Mark Adams, Eleanor Davyson, Matthew Iveson, Andrew M McIntosh and Xueyi Shen
(2023)
DOI: 10.1101/2023.09.07.555071
Voir cet article

Comprehensive in vitro and in silico assessments of metabolic capabilities of 24 genomic variants of CYP2C19 using two different substrates

Myung-Eui Seo, Byung-Joo Min, Nayoon Heo, Kye Hwa Lee and Ju Han Kim
Frontiers in Pharmacology 14 (2023)
DOI: 10.3389/fphar.2023.1055991
Voir cet article

A.W. Jones, F. Musshoff, T. Krämer, A. E. Steuer, D. Gerostamoulos, O.H. Drummer, G. Drasch, M. Balikova, J. Beyer, H. Teixeira, M. Thevis, W. Schänzer, H. Druid and G. Skopp
1167 (2022)
DOI: 10.1002/9781119648628.ch52
Voir cet article

Síndrome de Activación en Niños y Adolescentes Tratados con Inhibidores Selectivos de la Recaptación de Serotonina

Diana Marcela Pulzara Velasco and Laura Ospina Pinillos
Revista Colombiana de Psiquiatría (2022)
DOI: 10.1016/j.rcp.2022.03.005
Voir cet article

An electrophysiological model of major depression: Relevance to clinical subtyping and pharmacological management

Ivo H. Cerda and Paul J. Fitzgerald
Psychiatry Research 303 114054 (2021)
DOI: 10.1016/j.psychres.2021.114054
Voir cet article

Drug repurposing of selective serotonin reuptake inhibitors: Could these drugs help fight COVID-19 and save lives?

Yaser Pashaei
Journal of Clinical Neuroscience 88 163 (2021)
DOI: 10.1016/j.jocn.2021.03.010
Voir cet article

Therapy response prediction in major depressive disorder: current and novel genomic markers influencing pharmacokinetics and pharmacodynamics

Alena Shalimova, Viktoria Babasieva, Vladimir N Chubarev, Vadim V Tarasov, Helgi B Schiöth and Jessica Mwinyi
Pharmacogenomics 22 (8) (2021)
DOI: 10.2217/pgs-2020-0157
Voir cet article

Examination and characterisation of the effect of amitriptyline therapy for chronic neuropathic pain on neuropeptide and proteomic constituents of human cerebrospinal fluid

Jonathan Royds, Hilary Cassidy, Melissa J. Conroy, et al.
Brain, Behavior, & Immunity - Health 10 100184 (2021)
DOI: 10.1016/j.bbih.2020.100184
Voir cet article

Defining screening panel of functional variants of CYP1A1, CYP2C9, CYP2C19, CYP2D6, and CYP3A4 genes in Serbian population

Ivan Skadrić and Oliver Stojković
International Journal of Legal Medicine 134 (2) 433 (2020)
DOI: 10.1007/s00414-019-02234-7
Voir cet article

Multi-Ethnic Analysis of Cardiac Pharmacogenetic Markers of Cytochrome P450 and Membrane Transporters Genes in the Russian Population

K. B. Mirzaev, D. S. Fedorinov, D. V. Ivashchenko and D. A. Sychev
Rational Pharmacotherapy in Cardiology 15 (3) 393 (2019)
DOI: 10.20996/1819-6446-2019-15-3-393-406
Voir cet article

ADME pharmacogenetics: future outlook for Russia

Karin B Mirzaev, Denis S Fedorinov, Dmitry V Ivashchenko and Dmitry A Sychev
Pharmacogenomics 20 (11) 847 (2019)
DOI: 10.2217/pgs-2019-0013
Voir cet article

Effects of Digeda-4 Decoction on the CYP450 Activities in Rats Using a Cocktail Method by HPLC

Dong Zhang, Guo-dong Wu, Yan-dong Zhang, et al.
BioMed Research International 2018 1 (2018)
DOI: 10.1155/2018/1415082
Voir cet article

Pharmacie Clinique et Thérapeutique

Hélène Peyrière
Pharmacie Clinique et Thérapeutique 665 (2018)
DOI: 10.1016/B978-2-294-75077-9.00038-4
Voir cet article

In Vitro Functional Characterisation of Cytochrome P450 (CYP) 2C19 Allelic Variants CYP2C1923 and CYP2C1924

Pui Shen Lau, Kenny Voon Gah Leong, Chin Eng Ong, Amelia Nathania Hui Min Dong and Yan Pan
Biochemical Genetics 55 (1) 48 (2017)
DOI: 10.1007/s10528-016-9771-8
Voir cet article

Psychotropic drugs and CYP2D6 in late-life psychiatric and neurological disorders. What do we know?

Davide Seripa, Madia Lozupone, Eleonora Stella, et al.
Expert Opinion on Drug Safety 16 (12) 1373 (2017)
DOI: 10.1080/14740338.2017.1389891
Voir cet article

Melatonin and pro-hypnotic effectiveness of the antidepressant Trazodone: A preliminary evaluation in insomniac mood-disorder patients

Gino Giannaccini, Irene Masala, Lionella Palego, et al.
Clinical Biochemistry 49 (15) 1152 (2016)
DOI: 10.1016/j.clinbiochem.2016.06.014
Voir cet article

Effect of 24 cytochrome P450 2D6 variants found in the Chinese population on the N-demethylation of amitriptyline in vitro

Qinghua Weng, Bingqing Liang, Yali Zhou, et al.
Pharmaceutical Biology 54 (11) 2475 (2016)
DOI: 10.3109/13880209.2016.1160250
Voir cet article

Acute fluoxetine modulates emotional processing in young adult volunteers

L. P. Capitão, S. E. Murphy, M. Browning, P. J. Cowen and C. J. Harmer
Psychological Medicine 45 (11) 2295 (2015)
DOI: 10.1017/S0033291715000240
Voir cet article

SSRI-Induced Activation Syndrome in Children and Adolescents—What Is Next?

Maya Amitai, Alon Chen, Abraham Weizman and Alan Apter
Current Treatment Options in Psychiatry 2 (1) 28 (2015)
DOI: 10.1007/s40501-015-0034-9
Voir cet article

Cytochrome P450 enzymes in drug metabolism: Regulation of gene expression, enzyme activities, and impact of genetic variation

Ulrich M. Zanger and Matthias Schwab
Pharmacology & Therapeutics 138 (1) 103 (2013)
DOI: 10.1016/j.pharmthera.2012.12.007
Voir cet article

Personalized Treatment of Pain

Jacob N. Ablin and Dan Buskila
Current Rheumatology Reports 15 (1) (2013)
DOI: 10.1007/s11926-012-0298-7
Voir cet article

The neurobiology of depression and antidepressant action

Paul Willner, Jørgen Scheel-Krüger and Catherine Belzung
Neuroscience & Biobehavioral Reviews 37 (10) 2331 (2013)
DOI: 10.1016/j.neubiorev.2012.12.007
Voir cet article

PharmGKB summary

Stuart A. Scott, Katrin Sangkuhl, Alan R. Shuldiner, et al.
Pharmacogenetics and Genomics 22 (2) 159 (2012)
DOI: 10.1097/FPC.0b013e32834d4962
Voir cet article

Ulrich M. Zanger
1 (2012)
DOI: 10.1002/9780470921920.edm009
Voir cet article

293 (2012)
DOI: 10.1002/9781118347867.ch14
Voir cet article

CYP2C19 activity comparison between Swedes and Koreans: effect of genotype, sex, oral contraceptive use, and smoking

Margareta Ramsjö, Eleni Aklillu, Lilleba Bohman, et al.
European Journal of Clinical Pharmacology 66 (9) 871 (2010)
DOI: 10.1007/s00228-010-0835-0
Voir cet article

Combining antidepressants: understanding drug interactions is the sine qua non

Ken Gillman
Advances in Psychiatric Treatment 16 (1) 76 (2010)
DOI: 10.1192/apt.16.1.76
Voir cet article

Antidepressant-Induced Suicidality: An Update

Roy R. Reeves and Mark E. Ladner
CNS Neuroscience & Therapeutics no (2010)
DOI: 10.1111/j.1755-5949.2010.00160.x
Voir cet article

Schizophrenie — Zukunftsperspektiven in Klinik und Forschung

Brigitta Bondy, I. Spellmann, R. Musil, et al.
Schizophrenie — Zukunftsperspektiven in Klinik und Forschung 219 (2010)
DOI: 10.1007/978-3-211-92215-6_17
Voir cet article

The Promise and Reality of Pharmacogenetics in Psychiatry

Peter P. Zandi and Jennifer T. Judy
Clinics in Laboratory Medicine 30 (4) 931 (2010)
DOI: 10.1016/j.cll.2010.07.004
Voir cet article

Is elevated norepinephrine an etiological factor in some cases of epilepsy?

Paul J. Fitzgerald
Seizure 19 (6) 311 (2010)
DOI: 10.1016/j.seizure.2010.04.011
Voir cet article

The Promise and Reality of Pharmacogenetics in Psychiatry

Peter P. Zandi and Jennifer T. Judy
Psychiatric Clinics of North America 33 (1) 181 (2010)
DOI: 10.1016/j.psc.2009.12.001
Voir cet article

The CYP2C19*17 genotype is associated with lower imipramine plasma concentrations in a large group of depressed patients

P W Schenk, M van Vliet, R A A Mathot, T van Gelder, A G Vulto, M A C van Fessem, S Verploegh-Van Rij, J Lindemans, J A Bruijn and R H N van Schaik
The Pharmacogenomics Journal 10 (3) 219 (2010)
DOI: 10.1038/tpj.2009.50
Voir cet article

Is norepinephrine an etiological factor in some types of cancer?

Paul J. Fitzgerald
International Journal of Cancer 124 (2) 257 (2009)
DOI: 10.1002/ijc.24063
Voir cet article

Azoles and antidepressants: a mini-review of the tolerability of co-administration

P. Roussos, R. E. Lewis and D. P. Kontoyiannis
Mycoses 52 (5) 433 (2009)
DOI: 10.1111/j.1439-0507.2008.01677.x
Voir cet article

Estimating the Danish Populations' Preferences for Pharmacogenetic Testing Using a Discrete Choice Experiment. The Case of Treating Depression

Louise Herbild, Mickael Bech and Dorte Gyrd-Hansen
Value in Health 12 (4) 560 (2009)
DOI: 10.1111/j.1524-4733.2008.00465.x
Voir cet article

Cooperative opioid and serotonergic mechanisms generate superior antidepressant-like effects in a mice model of depression

Esther Berrocoso and Juan-Antonio Mico
The International Journal of Neuropsychopharmacology 12 (08) 1033 (2009)
DOI: 10.1017/S1461145709000236
Voir cet article

Neuropeptide and Sigma Receptors as Novel Therapeutic Targets for the Pharmacotherapy of Depression

Konstantinos A. Paschos, Stavroula Veletza and Ekaterini Chatzaki
CNS Drugs 23 (9) 755 (2009)
DOI: 10.2165/11310830-000000000-00000
Voir cet article

Is elevated noradrenaline an aetiological factor in a number of diseases?

P. J. Fitzgerald
Autonomic and Autacoid Pharmacology 29 (4) 143 (2009)
DOI: 10.1111/j.1474-8665.2009.00442.x
Voir cet article

The clinical role of genetic polymorphisms in drug-metabolizing enzymes

D Tomalik-Scharte, A Lazar, U Fuhr and J Kirchheiner
The Pharmacogenomics Journal 8 (1) 4 (2008)
DOI: 10.1038/sj.tpj.6500462
Voir cet article

Patient preferences for pharmacogenetic screening in depression

Louise Herbild, Dorte Gyrd-Hansen and Mickael Bech
International Journal of Technology Assessment in Health Care 24 (01) 96 (2008)
DOI: 10.1017/S0266462307080129
Voir cet article

Association of graded allele-specific changes in CYP2D6 function with imipramine dose requirement in a large group of depressed patients

P W Schenk, M A C van Fessem, S Verploegh-Van Rij, R A A Mathot, T van Gelder, A G Vulto, M van Vliet, J Lindemans, J A Bruijn and R H N van Schaik
Molecular Psychiatry 13 (6) 597 (2008)
DOI: 10.1038/sj.mp.4002057
Voir cet article

The CYP2D6 polymorphism in relation to the metabolism of amitriptyline and nortriptyline in the Faroese population

Jónrit Halling, Pál Weihe and Kim Brosen
British Journal of Clinical Pharmacology 65 (1) 134 (2008)
DOI: 10.1111/j.1365-2125.2007.02969.x
Voir cet article

Pharmacogenomics and migraine: possible implications

Peer Tfelt-Hansen and Kim Brøsen
The Journal of Headache and Pain 9 (1) 13 (2008)
DOI: 10.1007/s10194-008-0009-y
Voir cet article

Functional pharmacogenetics/genomics of human cytochromes P450 involved in drug biotransformation

Ulrich M. Zanger, Miia Turpeinen, Kathrin Klein and Matthias Schwab
Analytical and Bioanalytical Chemistry 392 (6) 1093 (2008)
DOI: 10.1007/s00216-008-2291-6
Voir cet article

SSRI adverse events: How to monitor and manage

Tanya K. Murphy, Ana Segarra, Eric A. Storch and Wayne K. Goodman
International Review of Psychiatry 20 (2) 203 (2008)
DOI: 10.1080/09540260801889211
Voir cet article

Pharmacokinetic Genes Do Not Influence Response or Tolerance to Citalopram in the STAR*D Sample

Eric J. Peters, Susan L. Slager, Jeffrey B. Kraft, et al.
PLoS ONE 3 (4) e1872 (2008)
DOI: 10.1371/journal.pone.0001872
Voir cet article

Correlation of inter-individual variations of amitriptyline metabolism examined in hairs with CYP2C19 and CYP2D6 polymorphisms

Detlef Thieme, Burkhard Rolf, Hans Sachs and Dagmar Schmid
International Journal of Legal Medicine 122 (2) 149 (2008)
DOI: 10.1007/s00414-007-0184-4
Voir cet article

Pharmacogenetics of antipsychotics: useful for the clinician?

Brigitta Bondy and Ilja Spellmann
Current Opinion in Psychiatry 20 (2) 126 (2007)
DOI: 10.1097/YCO.0b013e328017f69f
Voir cet article

Workshop outcomes report: Initiatives to establish a European Network of pharmacogenetics/genomics and progress

Anke Hilse Maitland-van der Zee, Katherine Aitchison and Julia Kirchheiner
European Journal of Pharmaceutical Sciences 31 (3-4) 151 (2007)
DOI: 10.1016/j.ejps.2007.03.009
Voir cet article

Tricyclic antidepressant pharmacology and therapeutic drug interactions updated

P K Gillman
British Journal of Pharmacology 151 (6) 737 (2007)
DOI: 10.1038/sj.bjp.0707253
Voir cet article

Review of evidence for genetic testing for CYP450 polymorphisms in management of patients with nonpsychotic depression with selective serotonin reuptake inhibitors

Mugdha Thakur, Iris Grossman, Douglas C McCrory, et al.
Genetics in Medicine 9 (12) 826 (2007)
DOI: 10.1097/GIM.0b013e31815bf98f
Voir cet article

Risk of adverse behavioral effects with pediatric use of antidepressants

Wayne K. Goodman, Tanya K. Murphy and Eric A. Storch
Psychopharmacology 191 (1) 87 (2007)
DOI: 10.1007/s00213-006-0642-6
Voir cet article

Routine pharmacogenetic testing in clinical practice: dream or reality?

Iris Grossman
Pharmacogenomics 8 (10) 1449 (2007)
DOI: 10.2217/14622416.8.10.1449
Voir cet article

Treatment of depression with selective serotonin inhibitors: the role of fluvoxamine

Stefano Pallanti and Cláudio Sandner
International Journal of Psychiatry in Clinical Practice 11 (3) 233 (2007)
DOI: 10.1080/13651500701419685
Voir cet article

Therapeutic Drug Monitoring of Antidepressants and Cytochrome P450 Genotyping in General Practice

Jenny E. Kootstra-Ros, Marga J. M. Van Weelden, John W. J. Hinrichs, Peter A. G. M. De Smet and Jan van der Weide
The Journal of Clinical Pharmacology 46 (11) 1320 (2006)
DOI: 10.1177/0091270006293754
Voir cet article

A Poor Metabolizer for Cytochromes P450 2D6 and 2C19: A Case Report on Antidepressant Treatment

Maria Johnson, Courtney Markham-Abedi, Margaret T. Susce, et al.
CNS Spectrums 11 (10) 757 (2006)
DOI: 10.1017/S1092852900014887
Voir cet article

Tolerability and safety of fluvoxamine and other antidepressants

H. G. M. Westenberg and C. Sandner
International Journal of Clinical Practice 60 (4) 482 (2006)
DOI: 10.1111/j.1368-5031.2006.00865.x
Voir cet article

Drug-induced changes in P450 enzyme expression at the gene expression level: A new dimension to the analysis of drug–drug interactions

M. D. Lee, E. Ayanoglu and L. Gong
Xenobiotica 36 (10-11) 1013 (2006)
DOI: 10.1080/00498250600861785
Voir cet article

Clinical Guidelines for Psychiatrists for the Use of Pharmacogenetic Testing for CYP450 2D6 and CYP450 2C19

Jose de Leon, Scott C. Armstrong and Kelly L. Cozza
Psychosomatics 47 (1) 75 (2006)
DOI: 10.1176/appi.psy.47.1.75
Voir cet article

CYP2D6 and CYP2C19 genotypes and amitriptyline metabolite ratios in a series of medicolegal autopsies

Anna Koski, Johanna Sistonen, Ilkka Ojanperä, et al.
Forensic Science International 158 (2-3) 177 (2006)
DOI: 10.1016/j.forsciint.2005.05.032
Voir cet article

Use of an online surveillance system for screening drug interactions in prescriptions in community pharmacies

Tiina Heikkilä, Tuula Lekander and Hannu Raunio
European Journal of Clinical Pharmacology 62 (8) 661 (2006)
DOI: 10.1007/s00228-006-0149-4
Voir cet article

Dose escalation for insufficient response to standard-dose selective serotonin reuptake inhibitors in major depressive disorder

Henricus G. Ruhé, Jochanan Huyser, Jan A. Swinkels and Aart H. Schene
British Journal of Psychiatry 189 (4) 309 (2006)
DOI: 10.1192/bjp.bp.105.018325
Voir cet article

The Dosing of Atypical Antipsychotics

Jose de Leon, Scott C. Armstrong and Kelly L. Cozza
Psychosomatics 46 (3) 262 (2005)
DOI: 10.1176/appi.psy.46.3.262
Voir cet article

Re: no evidence of increased adverse drug reactions in cytochrome P450CYP2D6 poor metabolizers treated with fluoxetine or nortriptyline

P. K. Gillman
Human Psychopharmacology: Clinical and Experimental 20 (1) 61 (2005)
DOI: 10.1002/hup.659
Voir cet article

Article cité par

Article cité :

Some Aspects of Genetic Polymorphism in the Biotransformation of Antidepressants

Citations de cet article :

Effectiveness of Genotype-Specific Tricyclic Antidepressant Dosing in Patients With Major Depressive Disorder

Comprehensive in vitro and in silico assessments of metabolic capabilities of 24 genomic variants of CYP2C19 using two different substrates

Síndrome de Activación en Niños y Adolescentes Tratados con Inhibidores Selectivos de la Recaptación de Serotonina

An electrophysiological model of major depression: Relevance to clinical subtyping and pharmacological management

Drug repurposing of selective serotonin reuptake inhibitors: Could these drugs help fight COVID-19 and save lives?

Therapy response prediction in major depressive disorder: current and novel genomic markers influencing pharmacokinetics and pharmacodynamics

Examination and characterisation of the effect of amitriptyline therapy for chronic neuropathic pain on neuropeptide and proteomic constituents of human cerebrospinal fluid

Defining screening panel of functional variants of CYP1A1, CYP2C9, CYP2C19, CYP2D6, and CYP3A4 genes in Serbian population

Multi-Ethnic Analysis of Cardiac Pharmacogenetic Markers of Cytochrome P450 and Membrane Transporters Genes in the Russian Population

ADME pharmacogenetics: future outlook for Russia

Effects of Digeda-4 Decoction on the CYP450 Activities in Rats Using a Cocktail Method by HPLC

Pharmacie Clinique et Thérapeutique

In Vitro Functional Characterisation of Cytochrome P450 (CYP) 2C19 Allelic Variants CYP2C19*23 and CYP2C19*24

Psychotropic drugs and CYP2D6 in late-life psychiatric and neurological disorders. What do we know?

Melatonin and pro-hypnotic effectiveness of the antidepressant Trazodone: A preliminary evaluation in insomniac mood-disorder patients

Effect of 24 cytochrome P450 2D6 variants found in the Chinese population on the N-demethylation of amitriptyline in vitro

Acute fluoxetine modulates emotional processing in young adult volunteers

SSRI-Induced Activation Syndrome in Children and Adolescents—What Is Next?

Cytochrome P450 enzymes in drug metabolism: Regulation of gene expression, enzyme activities, and impact of genetic variation

Personalized Treatment of Pain

The neurobiology of depression and antidepressant action

PharmGKB summary

CYP2C19 activity comparison between Swedes and Koreans: effect of genotype, sex, oral contraceptive use, and smoking

Combining antidepressants: understanding drug interactions is the sine qua non

Antidepressant-Induced Suicidality: An Update

Schizophrenie — Zukunftsperspektiven in Klinik und Forschung

The Promise and Reality of Pharmacogenetics in Psychiatry

Is elevated norepinephrine an etiological factor in some cases of epilepsy?

The Promise and Reality of Pharmacogenetics in Psychiatry

The CYP2C19*17 genotype is associated with lower imipramine plasma concentrations in a large group of depressed patients

Is norepinephrine an etiological factor in some types of cancer?

Azoles and antidepressants: a mini-review of the tolerability of co-administration

Estimating the Danish Populations' Preferences for Pharmacogenetic Testing Using a Discrete Choice Experiment. The Case of Treating Depression

Cooperative opioid and serotonergic mechanisms generate superior antidepressant-like effects in a mice model of depression

Neuropeptide and Sigma Receptors as Novel Therapeutic Targets for the Pharmacotherapy of Depression

Is elevated noradrenaline an aetiological factor in a number of diseases?

The clinical role of genetic polymorphisms in drug-metabolizing enzymes

Patient preferences for pharmacogenetic screening in depression

Association of graded allele-specific changes in CYP2D6 function with imipramine dose requirement in a large group of depressed patients

The CYP2D6 polymorphism in relation to the metabolism of amitriptyline and nortriptyline in the Faroese population

Pharmacogenomics and migraine: possible implications

Functional pharmacogenetics/genomics of human cytochromes P450 involved in drug biotransformation

SSRI adverse events: How to monitor and manage

Pharmacokinetic Genes Do Not Influence Response or Tolerance to Citalopram in the STAR*D Sample

Correlation of inter-individual variations of amitriptyline metabolism examined in hairs with CYP2C19 and CYP2D6 polymorphisms

Pharmacogenetics of antipsychotics: useful for the clinician?

Workshop outcomes report: Initiatives to establish a European Network of pharmacogenetics/genomics and progress

Tricyclic antidepressant pharmacology and therapeutic drug interactions updated

Review of evidence for genetic testing for CYP450 polymorphisms in management of patients with nonpsychotic depression with selective serotonin reuptake inhibitors

Risk of adverse behavioral effects with pediatric use of antidepressants

Routine pharmacogenetic testing in clinical practice: dream or reality?

Treatment of depression with selective serotonin inhibitors: the role of fluvoxamine

Therapeutic Drug Monitoring of Antidepressants and Cytochrome P450 Genotyping in General Practice

A Poor Metabolizer for Cytochromes P450 2D6 and 2C19: A Case Report on Antidepressant Treatment

Tolerability and safety of fluvoxamine and other antidepressants

Drug-induced changes in P450 enzyme expression at the gene expression level: A new dimension to the analysis of drug–drug interactions

Clinical Guidelines for Psychiatrists for the Use of Pharmacogenetic Testing for CYP450 2D6 and CYP450 2C19

CYP2D6 and CYP2C19 genotypes and amitriptyline metabolite ratios in a series of medicolegal autopsies

Use of an online surveillance system for screening drug interactions in prescriptions in community pharmacies

Dose escalation for insufficient response to standard-dose selective serotonin reuptake inhibitors in major depressive disorder

The Dosing of Atypical Antipsychotics

Re: no evidence of increased adverse drug reactions in cytochrome P450CYP2D6 poor metabolizers treated with fluoxetine or nortriptyline

In Vitro Functional Characterisation of Cytochrome P450 (CYP) 2C19 Allelic Variants CYP2C1923 and CYP2C1924